Skip to content

Cerebrospinal Fluid and MRI Analyses of Fenebrutinib Treatment in Multiple Sclerosis Reveal Brain Penetration and Early Reduction of New Lesion Activity: Results from the Phase II FENopta study

Bruton’s tyrosine kinase (BTK) is implicated in peripheral and central nervous system inflammation in multiple sclerosis (MS) and is a therapeutic target for relapsing and progressive disease. Fenebrutinib is a potent, highly selective, noncovalent, reversible BTK inhibitor under investigation for MS. The objective of FENopta, a randomised, double-blind, placebo-controlled, Phase 2 trial (NCT05119569), was to evaluate efficacy and safety of fenebrutinib in relapsing MS and evaluate the early impact of fenebrutinib on MRI outcomes and soluble markers of disease activity and progression.

{{assetTitle}}

Authors {{assetAuthors}}

Published date{{formattedPublishDate}}

{{assetDescription}}

Send Via Email

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

Leave Site

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.

Leave Site Stay on Medically